05 February 2020 | News
Newest isotretinoin formulation features micronization technology to optimize absorption at a lower dose
image credit- shuttershock.com
Sun Pharmaceutical Industries Ltd. has announced that one of its wholly owned subsidiaries has launched ABSORICA LD™ (isotretinoin) capsules in U.S. for the management of severe recalcitrant nodular acne in patients 12 years of age and older.
ABSORICA LD is the only isotretinoin formulation to feature Sun Pharma’s micronization technology, which utilizes micronized particles to optimize absorption at a 20% lower dose. ABSORICA LD can be taken with or without food.
“The launch of ABSORICA LD – which offers the proven efficacy and safety of ABSORICA® at a lower dose – underscores our commitment to making a difference in the lives of people with severe recalcitrant nodular acne,” said Abhay Gandhi, CEO, North America, Sun Pharma.
“Severe recalcitrant nodular acne is characterized by nodules, which are hard, solid, painful lumps in the skin, and primarily affects teens and young adults,” noted Nicholas Squittieri, MD, Chief Medical Officer, North America, Sun Pharma. “Ineffective acne treatment can cause lifelong physical scars as well as psychosocial issues such as feelings of isolation. ABSORICA LD makes visibly clearer skin possible within just five months, removes the uncertainty surrounding timing of dosing, and makes absorption more predictable. The availability of a low-dose, highly bioavailable oral isotretinoin option should be welcome news for those suffering from this very severe form of acne.”